PFIZER INC 8-K

What Happened
Pfizer Inc. announced its financial results for the fourth quarter of 2025 in a press release dated February 3, 2026. The company furnished that press release as Exhibit 99 to an 8-K (Item 2.02) filed February 3, 2026; the release is incorporated by reference in the filing. The 8-K was signed by Margaret M. Madden, Senior Vice President and Corporate Secretary.

Key Details

• Filing date: February 3, 2026 (Form 8-K).
• Item reported: 2.02 — Results of Operations and Financial Condition (press release announcing Q4 2025 results).
• Exhibit: No. 99 — Press Release dated February 3, 2026 reporting Pfizer’s Q4 2025 results; Exhibit 104 — Inline XBRL cover page tags.
• Signature: Executed by Margaret M. Madden, Senior Vice President and Corporate Secretary.

Why It Matters
This 8-K notifies investors that Pfizer has publicly reported its quarterly earnings and related financial information for Q4 2025. Retail investors should review the Exhibit 99 press release for the specific figures (revenue, earnings per share, guidance or commentary) and any management commentary that could affect near-term stock expectations or investment decisions.